Community/Retail

In this third video in a series collaboration between Pharmacy Times and USP, Jeanne Sun, PharmD, JD, counsel, legal at USP, discusses information to help pharmacists counsel patients on quality expectations in the pharmacy.

Donanemab induced rapid amyloid plaque reduction at 24 weeks in patients with early symptomatic Alzheimer disease, with the most rapid clearance in patients with the most severe plaque burden at baseline.

John M. O’Brien, PharmD, MPH, newly appointed President and CEO of the National Pharmaceutical Council, shares his view of what pharmacists contribute to health care.

In the study, ritlecitinib 50 mg and 30 mg achieved the primary efficacy endpoint, specifically the proportion of patients with less than or equal to 20% scalp hair loss after 6 months of treatment versus placebo.

Though the benefits of continuous glucose monitoring for patients with diabetes has been previously demonstrated, the investigators said that these benefits have only been well-established for patients with type 1 diabetes or patients with type 2 diabetes treated with multiple daily insulin injections.

ACE inhibitors are currently prescribed more commonly than ARBs as a first-time blood pressure control medicine despite this difference in AEs, the study authors noted.

Patients on metformin should check their vitamin B12 levels on regular basis to make sure it is at normal range.

Thomas Maggio, MBA, public affairs and engagement manager at AACP, discussed his presentation assessing the Opioid-Related Activity Database and its impact in showing the efforts of pharmacists and student pharmacists to fight the opioid epidemic.

John M. O’Brien, PharmD, MPH, newly appointed President and CEO of the National Pharmaceutical Council, discusses the 3 main insights that have guided him throughout his career.

Clive Ward Able, MD, BPharm, discusses research results suggesting the promise of psilocybin as a potential treatment for obesity.

Trials were conducted on participants with the chronic digestive condition to assess whether vitamin D reduced the severity of their symptoms and whether it could improve their quality of life.

The analysis used AstraZeneca’s global safety database, which contains all spontaneously reported adverse events from real-world use of its medicines and vaccines worldwide.

Anifrolumab is a first-in-class type I interferon receptor antibody and is the only new treatment in more than a decade for this patient population.

The gluten-like proteins found in ryegrass could be interacting with crops commonly used as wheat replacements, which may cause a reaction among people with celiac or gluten intolerance.

John M. O’Brien, PharmD, MPH, newly appointed President and CEO of the National Pharmaceutical Council, discusses his plans for the future of the organization.

Complications of varicella-zoster virus in patients with lupus may be attributable to immunological abnormalities, lymphopenia conditions, and immunosuppressive therapies.

You read that correctly; drop the zero in 20 to explain spending in the sector in the near future.

The investigators noted that the levels of islatravir in peripheral blood mononuclear cells remained above the efficacy pharmacokinetics threshold for PrEP for both doses studied (60 mg and 120 mg) for 8 weeks following the last study dose.

Vviloxazine (Qelbree) is a norepinephrine reuptake inhibitor that provides a new treatment option for patients aged 6 to 17 years with ADHD.

Reducing blood pressure is the major determinant of reduction in cardiovascular risk in both young and older patients with hypertension.

Penny pinchers, early arrivals, and more are featured in this month's Pet Peeves.

The FDA has approved the monoclonal antibody mepolizumab as a treatment for patients with chronic rhinosinusitis with nasal polyps.

This month's products include a smart pen cap for insulin dosing, a treatment for benign prostatic hyperplasia, and more.

Lipophilic statins for dyslipidemia penetrate muscle more easily than hydrophilic statins and are associated with a higher incidence of adverse effects.

On average, those who received a flu-like diagnosis changed their cell phone usage behavior 1 day before their diagnosis and the 2 to 4 days afterward.

The availability of insulin biosimilars can bring high-quality, lower cost treatment options for pharmacists, physicians, payers, and patients alike.

John M. O’Brien, PharmD, MPH, newly appointed President and CEO of the National Pharmaceutical Council, discusses what led to his interest in the position.

Companies and practitioners should take important steps to protect patients from these mistakes.